$FDMT

Analysts remain cautiously optimistic, favoring utilities, healthcare, and infrastructure. 4D Molecular Therapeutics (FDMT) and Abbott Laboratories (ABT) received multiple ratings. ABT's price targets varied, with some raised and others lowered. Other notable updates include downgrades for Aegon (AEG) and Alcoa (AA), while Alphabet (GOOGL) saw a lowered target. Sector-specific trends and individual stock ratings reflect varying market outlooks.

4D Molecular Therapeutics (FDMT) reported that its Phase III trials for 4D-150 gene therapy for wet AMD are fully enrolled, with 523 patients in North America and 531 globally. The primary endpoint is non-inferiority in visual acuity compared to aflibercept. The company expects results in 2027 and has a cash runway into 2028.

4D Molecular Therapeutics (4DMT) granted 13 new non-executive employees options to buy 260,000 shares and 157,600 RSUs. The biotech company focuses on gene therapies for retinal and cystic fibrosis diseases, with lead candidates 4D-150 and 4D-710 in clinical development.

Analysts from Barclays, Wells Fargo, and Chardan Capital provided ratings and price targets for 4D Molecular Therapeutics (FDMT), Pfizer (PFE), and Incyte (INCY). FDMT has a Strong Buy consensus with a $31.25 avg. target. PFE has a Moderate Buy consensus with a $29.62 avg. target. INCY has a Moderate Buy consensus with a $132.58 avg. target.

Kirn David (See Remarks) sold 58,333 shares of 4D Molecular Therapeutics, Inc. (FDMT) at an average of $12.92 ($12.92–$13.61, $0.75M total) across 2 trades on 2026-10-05 under a Rule 10b5-1 trading plan.

B.Riley reiterated a Buy rating and $37.00 price target on 4D Molecular Therapeutics (FDMT), citing trial design and potential for its gene therapy candidate 4D-150. The company's market cap is $791 million, with shares up 91% year-to-date. Analysts highlight strong cash position, upcoming trial readouts, and potential adoption in wet AMD and diabetic macular edema.

Ocular Therapeutix (OCUL) shares dropped 22% as competitors Kodiak Sciences (KOD) and 4D Molecular Therapeutics (FDMT) reported positive updates on their wet AMD treatments. KOD's DAYBREAK study met goals, while FDMT's 4D-150 showed lasting benefits. OCUL's AXPAXLI is in development, with FDA filing planned for late 2026.

4D Molecular Therapeutics, Inc. (FDMT) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 28, 2026, 4D Molecular Therapeutics, Inc. (the “Company”) reported that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema (“DME”). The

Kirn David (See Remarks) sold 58,333 shares of 4D Molecular Therapeutics, Inc. (FDMT) at $13.90 ($0.81M total) on 2026-09-14 under a Rule 10b5-1 trading plan.

Compass Point upgraded Coinbase (COIN) to Neutral with a $177 price target, up from $130. Other upgrades include 4D Molecular Therapeutics (FDMT), Affirm (AFRM), Chime Financial (CHYM), and Bullish (BLSH) by their respective analysts. COIN closed at $175.26 on Friday.